Somatic reversion mutations and intragenic deletions restoring function of BRCA1 and BRCA2 in patients with known germline BRCA mutations have been well described in chemotherapy-resistant ovarian cancer [114,115]. Here, BRCA1 is linked to ovarian cancer.